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With advancements in the analytical technologies and methodologies in proteomics, there is
great interest in biomarker discovery in biofluids such as serum and plasma. Current
hypotheses suggest that the low molecular weight (LMW) serum proteome possesses an
archive of clipped and cleaved protein fragments that may provide insight into disease
development. Though these biofluids represent attractive samples from which new and more
accurate disease biomarkers may be found, the intrinsic person-to-person variability in these
samples complicates their discovery. Mice are one of the most extensively used animal models
for studying human disease because they represent a highly controllable experimental model
system. In this study, the LMW serum proteome was compared between xenografted
tumor-bearing mice and control mice by differential labeling utilizing trypsin-mediated
incorporation of the stable isotope of oxygen, 18O. The digestates were combined, fractionated
by strong cation exchange chromatography, and analyzed by nanoflow reversed-phase liquid
chromatography coupled online with tandem mass spectrometry, resulting in the identifica-
tion of 6003 proteins identified by at least a single, fully tryptic peptide. Almost 1650 proteins
were identified and quantitated by two or more fully tryptic peptides. The methodology
adopted in this work provides the means for future quantitative measurements in comparative
animal models of disease and in human disease cohorts. (J Am Soc Mass Spectrom 2005, 16,
1221–1230) © 2005 American Society for Mass SpectrometryBiomarker investigations are increasingly exploit-ing the developing technologies and methodolo-gies of proteomics with the hope of discovering
better indicators of the onset or progression of diseases.
Many investigations aim to discover biomarkers in
various biofluids (i.e., serum, plasma, and cerebrospinal
fluid) as these samples are easily obtainable, contain
high concentrations of proteins, and perfuse key tissues,
undoubtedly endowing these fluids with protein spe-
cies indicative of diseased states [1–4]. Hence, detection
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ent proteins in biofluids may provide the means for
disease detection, enabling earlier intervention in dis-
ease progression.
Much of the promise of proteomics for identification of
biomarkers in complex biological fluids can be traced to
seminal studies performed in John Yates’ laboratory. This
laboratory was the first to develop a high-throughput
method for large-scale proteome analysis, which com-
bined multidimensional liquid chromatography, tandem
mass spectrometry (MS/MS), and database searching by
the SEQUEST algorithm [5]. This method became popular
under the acronym MudPIT (i.e., multidimensional pro-
tein identification technology). MudPIT, or variations
thereof, has been used in countless studies to characterize
complex proteome samples, with the typical goal of ob-
taining as much possible information concerning the sam-
ple of interest. This technology has ushered in an era
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single sample [6, 7] and enables proteomics with the
technology to live up to its expectations of comprehensive
coverage of cellular proteins.
Perhaps the largest challenge posed in characterizing
the serum proteome arises from its inherently wide
dynamic range of protein concentration. Indeed, pro-
teins in serum have been estimated to be present across
9 orders of magnitude in concentration, in which only
22 species comprise almost 99% of the total protein
mass [8]. Logically, depletion of one or more of the high
abundance, high molecular weight proteins would as-
sist the detection and identification of low abundance
species. In an effort to decrease this dynamic range of
protein concentration, numerous affinity purification
and extraction methods have been developed to enrich
the smaller, less-abundant proteins and peptides in
complex biofluids [9, 10]. Recently, a simple methodol-
ogy was developed to deplete serum of high molecular
weight proteins by size partitioning through the use of
centrifugal ultrafilters [2]. The result was recovery of
what was coined the low molecular weight (LMW)
serum proteome. Microcapillary reversed-phase liquid
chromatography (RPLC) coupled online with tandem
mass spectrometry (MS/MS) enabled the identification
of greater than 880 peptides in this fraction, correspond-
ing to 340 proteins, which demonstrated the efficacy
of this method for the removal of large abundant
proteins and the enrichment of the LMW serum pro-
teome.
The work described herein expands upon the LMW
serum proteome enrichment methodology previously
developed in our laboratory to enable quantitative
measurements of peptide relative abundances between
serum samples utilizing trypsin-mediated 18O-labeling.
Specifically a quantitative analysis of the LMW serum
proteome from a murine model of human lung carci-
noma utilizing 18O stable isotope labeling and MS has
resulted in the identification and quantitation of 6003
proteins from 8992 unique tryptic peptides. This anal-
ysis establishes the basis for high throughput quantita-




Ammonium bicarbonate (NH4HCO3), ammonium for-
mate (NH4HCO2), formic acid (HCOOH), trifluoroace-
tic acid (TFA), and dithiothreitol (DTT) were purchased
from Sigma (St. Louis, MO). Porcine sequencing grade
modified trypsin was obtained from Promega (Madi-
son, WI). High performance liquid chromatography
(HPLC)-grade acetonitrile (CH3CN) was obtained from
EMD Chemicals Inc. (Gibbstown, NJ). All buffers and
reagents were used as supplied from the manufacturer
and prepared in double distilled water using a NANO-
Pure Diamond water system (Barnstead International,
Dubuque, IA).Mouse Tumor Xenograft Model
Mice were xenografted subcutaneously with 2  106
Lewis lung carcinoma cells in 100 l of medium or with
medium alone. Thirteen days following tumor implan-
tation or sham injection, blood was obtained by cardiac
puncture from 5 tumor-bearing mice and 5 control
(medium injected) mice, placed into Microtainer tubes
(Becton Dickinson, Franklin Lakes, NJ), allowed to clot,
and then centrifuged at 2500  g for 10 min. Serum was
aliquoted and stored at 80 °C until further use. Tu-
mors ranged in size from 250 to 300 mm at the time of
serum collection.
Low Molecular Weight Fractionation of Pooled
Mouse Serum Samples
Serum samples from each group of mice were pooled
and 500 l of each sample was diluted 20-fold with 50
mM NH4HCO3, pH 8.4, 20% CH3CN and incubated on
ice for 90 min with occasional gentle mixing. The low
molecular weight proteins were obtained by centrifugal
ultrafiltration using Centriplus ultrafilters (Milipore,
Billerica, MA) at 750  g at 4 °C until approximately
80% (8 mL) of the sample filtered through the mem-
brane. The filtrates were removed and stored at 20 °C
until further use. The retentates (approximately 2 mL)
were further diluted to 10 mL with 50 mM NH4HCO3,
pH 8.4, 20% CH3CN and incubated on ice for an
additional 2 h with occasional mixing. These samples
were fractionated as above overnight at 500  g at 4 °C.
Filtrates from both fractionations were pooled, lyophi-
lized and stored at 80 °C.
Tryptic Digestion
Total protein in each LMW serum sample was quanti-
fied using the BCA protein assay (Pierce, Rockford, IL)
and removal of the high molecular weight proteins was
confirmed by SDS-PAGE analysis of the pooled filtrates
and retentates. Equivalent amounts of each sample
(approximately 300 g) were diluted to 500 L with 25
mM NH4HCO3, pH 8.4. Freshly prepared 1 M DTT was
added to a final concentration of 10 mM and the
samples were boiled for 10 min. Trypsin was added at
an enzyme to protein ratio of 1:50 and each sample was
incubated for 16 h at 37 °C after which a second aliquot
of trypsin was added (enzyme to protein ratio of 1:50)
and the samples were incubated an additional 8 h at
37 °C.
Trypsin-Mediated 18O Labeling of Mouse
LMW Serum
The tryptically digested LMW serum proteins were
lyophilized and resuspended in 145 L of either 16O
(control) or 18O (lung carcinoma) water and 40 L of
methanol (20% (vol/vol) final concentration). Fifteen
L of trypsin, resuspended in the appropriately labeled
water, was added to each sample at an enzyme to
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16 h at 37 °C. Concentrated TFA was added to a final
concentration of 0.4% (vol/vol) and the mixtures were
boiled for 10 min. The samples were pooled and lyoph-
ilized prior to strong cation exchange (SCX) fraction-
ation.
Strong Cation Exchange Fractionation
Strong cation exchange fractionation was performed
using a HP 1090 LC system (Agilent Technologies, Palo
Alto, CA) equipped with a polysulfoethyl A column
(4.6  200 mm, 5 m, 300 Å pore size, PolyLC, Inc.,
Columbia, MD). The isotopically labeled mouse LMW
serum protein pool (600 g) was reconstituted in 10
mL 25% acetonitrile/0.1% formic acid and loaded onto
the column and washed with 2% mobile phase B for 12
min at a flow rate of 1.5 mL/min. The following
NH4HCO3/CH3CN multi-step gradient was used to
elute the peptides from the column at a flow rate of 1
mL/min: 2% mobile phase B (25% CH3CN, 0.5 M
NH4HCO3, pH 3.0) for 3 min, followed by 23% B in 70
min, then to 60% B in 15 min, and finally to 100% B in
1 min and maintained at 100% B for 7 min. Mobile
phase A was 25% CH3CN. Peptide separation was
monitored by fluorescence (280 nm excitation/350 nm
emission). Fractions were collected every minute, ly-
ophilized and reconstituted in 30 L of 0.1% (vol/vol)
TFA prior to nanoflow (nano) reversed-phase (RP)
liquid chromatography (LC)-tandem mass spectrome-
try (MS/MS) analysis.
Nanoflow Reversed-Phase Liquid Chromatography
Tandem Mass Spectrometry
Nanoflow RPLC analyses were performed using an
Agilent 1100 nanoLC system (Agilent Technologies)
coupled online to a linear ion trap (LIT) mass spectrom-
eter (LTQ, Thermo Electron, San Jose, CA) with the
nanoelectrospray interface supplied by the manufac-
turer. Separations were performed using 75 m i.d. 
360 m o.d. 10 cm long fused silica capillary columns
(Polymicro Technologies, Phoenix, AZ) that were slur-
ry-packed in-house with 3 m, 300 Å pore size C-18
silica-bonded stationary phase (Vydac, Hysperia, CA).
After injecting 7 L of sample, the column was washed
for 30 min with 98% mobile phase A (0.1% formic acid
in water) at a flow rate of 500 nL/min. Peptides were
eluted using a linear gradient of 2% mobile phase B
(0.1% formic acid in acetonitrile) to 40% mobile phase B
in 110 min, then to 98% B in an additional 30 min, all at
a constant flow rate of 200 nL/min.
The LIT mass spectrometer was operated in a data
dependent MS/MS mode in which each full MS scan
was followed by five MS/MS scans where the five most
abundant peptide molecular ions are dynamically se-
lected for collision-induced dissociation (CID) using a
normalized collision energy of 35%. Dynamic exclusionwas utilized to minimize redundant acquisition of pep-
tides previously selected for MS/MS. The heated cap-
illary temperature and electrospray voltage were set at
160 °C and 1.5 kV, respectively.
Bioinformatic Analysis
Tandem mass spectra were searched against the Uni-
Prot mouse proteomic database (05-12-04 release) from
the European Bioinformatics Institute (http://www.e-
bi.ac.uk/) with SEQUEST operating on an 18 node
Beowulf cluster. Peptides were searched using tryptic
cleavage constraints and a dynamic 4 Da modification
on the C-terminus. For a peptide to be considered
legitimately identified, it had to achieve stringent
charge state and proteolytic cleavage-dependent cross
correlation (Xcorr) scores of 1.9 for [M  H]
1, 2.2 for [M
 2H]2, 3.1 for [M  3H]3, and a minimum delta
correlation (Cn) of 0.08.
Results and Discussion
It is predicted that serum is likely to contain an abun-
dant archive of pathophysiological information because
of its constant perfusion through tissues [11]. A number
of published and ongoing proteomic investigations
have been, or are being, conducted of serum that will
usher in a new paradigm of understanding of this
complex and vital clinical sample. An interesting fea-
ture of many of the diagnostic studies that have em-
ployed various proteomic strategies is that, consis-
tently, proteins (and/or their fragments) that are
considered diagnostic for the disease of interest possess
low molecular weights, suggesting that the LMW se-
rum proteome may contain an unexplored archive of
histopathological information and provide useful bi-
omarkers for disease detection. Indeed, LMW serum
proteins, peptides, and other small components have
been associated with pathological conditions such as
cancer [12], diabetes [13], cardiovascular, and infectious
diseases [14]. A simple method for the enrichment of
the LMW components in serum has previously been
developed in our laboratory and used in conjunction
with multidimensional chromatographic fractionation
and MS analysis to better characterize this unexplored
fraction [2]. We have expanded this methodology in the
present work to incorporate trypsin-mediated 18O iso-
tope labeling to enable quantitative measurements of
the LMW serum proteome from a mouse model of
human lung carcinoma. The experimental design (Fig-
ure 1) relies on the ultrafiltration of two (or more)
serum samples, individually, to recover the LMW pro-
teomes to be quantitatively compared. In the present
case, each of the recovered LMW proteome samples
were first digested to completion with trypsin and
lyophilized to dryness. The control LMW proteome
sample was resuspended in a buffered solution pre-
pared in H2
16O and the lung carcinoma LMW proteome
sample was resuspended in the same buffered solution
1224 HOOD ET AL. J Am Soc Mass Spectrom 2005, 16, 1221–1230prepared in H2
18O. The addition of trypsin to these
samples serves to mediate the exchange of two equiv-
alents of 16O at the carboxy-terminus of each peptide
for two equivalents of 18O in the sample reconstituted
in H2
18O. Two complete enzyme turnovers in the
presence of H2
18O results in a 4 Da increase in mass of
each tryptic peptide [15–17]. The LMW proteome
digestates were combined, fractionated into 96 sam-
ples using SCXLC, and each analyzed by nanoRPLC-
Figure 1. Schematic representation of the exp
labeling of the mouse LMW serum proteome. The
serum and a pool from mice with lung carcin
acetonitrile incubation and utilizing molecular
proteomes were fully digested with trypsin
resuspended in buffered methanol and the lu
buffered methanol prepared in H2
18O and sep
samples were quenched in TFA, combined, fract
raphy, and analyzed by nanoRPLC-MS/MS.MS/MS.An important consideration in the extraction of the
LMW serum proteome is the extent to which high
abundant components are depleted. As shown in lane 2
of Figure 2, the most highly abundant proteins in serum
have molecular weights in excess of 45 kDa. Ultrafiltra-
tion of serum through a membrane with a 30 kDa
molecular weigh cutoff almost completely depletes
these proteins from the sample as shown through
coomassie staining of a SDS-PAGE gel (Figure 2, lane 3).
ntal design utilized for trypsin-mediated 18O-
serum proteome from a pool of control mouse
were each individually size fractionated after
ht cutoff ultrafilters. Each of the LMW serum
lyophilized. The control LMW digestate was
rcinoma LMW digestate was resuspended in
ly incubated with trypsin. Each of the LMW







ionatAlthough peptides assigned to high abundance pro-
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their abundance had been decreased to an extent to
which they no longer posed a challenge to the dynamic
range measurement capabilities of the combined off-
line MudPIT/MS system used in this study, in which
SCXLC is performed offline and separate from RPLC.
The identification of proteins with masses greater than
30 kDa in the low molecular weight fractions can be
attributed to the presence of proteolytic fragments of
the native proteins present within serum.
Critical to any study that utilizes a discovery-based
approach to find disease-specific biomarkers is the
ability to identify a large number of proteins that can be
used in a comparative analysis between samples. Pres-
ently, the largest databases of identified proteins from
either human serum or plasma contain between ap-
proximately 1450 [18] to 1700 proteins [19]. The proteins
in these studies, however, were identified from search-
Figure 2. SDS-PAGE analysis of high- and low-molecular weight
mouse serum purification. Tricine SDS-PAGE of the ultrafiltration
of mouse serum through a membrane with a 30 kDa molecular
weigh cutoff filter. Lane 2 shows the high-molecular weight
(HMW) retentate after filtration while lane 3 shows the low-
molecular weight eluate, which results in depletion of the majority
of the HMW proteins from the sample as shown through coom-
assie staining.ing MS/MS spectra in which multiple different enzymeconstraints were allowed and many of the proteins
were identified by a single peptide. In this study, almost
9000 fully tryptic peptides originating from 6003 pro-
teins were identified, making this in itself the largest
number of proteins identified in serum to date. To
assemble the list of peptide and protein identifications,
only those proteins identified by two or more tryptic
peptides that possess stringent Xcorr and Cn scores (as
described in the Experimental section) are reported.
Indeed, 1647 proteins were identified by at least two
unique, fully tryptic peptides, increasing the confidence
in those species identified in this manner. Over 500
proteins (i.e., 532) were identified by three or more
unique tryptic peptides, already surpassing the number
of proteins identified in a previous study in our labo-
ratory examining the LMW serum proteome. This large
increase in the number of tryptic peptides and total
proteins identified is a result of the resolution of the
SCX and RP separations as well as the use of a LIT mass
spectrometer, which has a much faster scan time than
the three-dimensional ion-trap mass spectrometer for
performing MS/MS experiments. This faster duty cycle
enables more peptides to be interrogated by CID per
unit time. A histogram showing the distribution of the
number of proteins identified per unique, fully tryptic
peptide is presented in Figure 3. Although it is well
accepted that many nontryptic peptides exist in serum,
identification of such peptides does not directly contrib-
ute to the present quantitative proteomic methodology,
based on the use of trypsin-mediated 18O labeling, and
are therefore excluded from the present analysis.
An important consideration when identifying pro-
teins in biofluids is that the characterization of the
identified species intuitively reflects the source of the
proteins. In the analysis of serum, one could expect an
enrichment of extracellular proteins compared to other
compartmental classes. In this study, 22% of the pro-
Figure 3. Proteins identified per number of unique, fully tryptic
peptides. Histogram showing the number of proteins identified in
the LMW mouse serum proteome per number of unique, fully
tryptic peptides. Of 6003 identified proteins, 1647 were identified
by two or more unique peptides.
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were classified as extracellular (Figure 4a). An addi-
tional 27% of the proteins were localized to the mem-
brane, with the remainder (i.e., 51%) originated from
intracellular compartments. Unfortunately, only about
30% of the proteins identified in this study by two or
more unique tryptic peptides could be linked to gene
ontology classifications. Gene ontology of the entire
mouse proteome (18,887 out of 27,459 possible proteins)
predicts that 14% of the proteins will be extracellular
(Figure 4b). Why there was a substantial increase in the
percentage of extracellular proteins observed in this
study compared to the mouse proteome is not clear.
Coincidentally, this same phenomenon was observed in
a gene ontology comparison of experimentally identi-
fied human serum proteins and the entire human
proteome [20].
An important factor when using 16O/18O labeling for
quantitative measurements is the completeness of en-
zyme-mediated isotope exchange. Shown in Figure 5a
and b are selected mass spectra of differentially labeled
LMW serum 16O/18O peptides from control mice and
those bearing Lewis lung carcinoma, indicating com-
plete 18O incorporation of peptides within serum ob-
tained from the mouse lung cancer model. These two
Figure 4. Gene ontology classification of cellular location of
mouse LMW serum proteins. (a) Cellular compartmentalization of
low molecular weight mouse serum proteins (30% mapped by
GO) reveal that 22% of these are classified as extracellular. (b)
Gene ontology classification predicts only 14% of the entire mouse
proteome encodes for extracellular proteins.sets of peptides were identified as apolipoprotein A1,which has recently been reported as a biomarker for the
detection of early stage ovarian cancer [21], and -1-
antitrypsin 1-1, which has been observed to have in-
creased levels in lung cancer patients [22], demonstrat-
ing the facile ability of the present methodology to
provide both quantitation and identification of putative
biomarkers in the same high-throughput experiment.
We hypothesize that efficient 18O incorporation, as
indicated by the mass spectra in Figure 5, may be
attributed to the observed increase (20%) in trypsin
activity in 20% (vol/vol) CH3OH as previously demon-
strated by a N-benzoyl-L-arginine ethyl ester trypsin
activity assay [23].
The identified peptides were quantified by calcu-
lating the relative abundances (18O/16O, in this data
set) of peptides based on the area of their extracted
ion chromatograms (XIC) reconstructed from the
molecular ion MS scans. There is no standard for
what change in relative abundance, as measured by
quantitative proteome analyses, represent statisti-
cally significant changes in protein abundance ratios.
This lack of a standard is because the determination
of isotopomeric peptide ratios depends directly on
many experimental factors, such as the equivalence of
the initial sample mixing, the relative efficiency of
recovery of each of the peptide pairs, the inherent
resolution and accuracy of the MS instrumentation,
and the number of molecular ion scans across each
peptide pair nanoRPLC peak. We sought to deter-
mine the threshold above and below which the mea-
sured protein abundance ratios were statistically sig-
nificant within this dataset. This analysis was
conducted by plotting the normalized percent of the
number of 18O/16O labeled proteins identified within
binned abundance ratios (e.g., 1.0-1.09, 1.1-1.19, etc.)
as determined from integration of each of the respec-
tive isotopomeric peptide pair XIC (Figure 6). Theo-
retically, the distribution of the protein abundance




e(x  )2⁄(22) (1)
where P is the normalized number of proteins identified
at a given protein abundance ratio x,  is defined as the
experimentally measured mean value of the total pop-
ulation of the protein abundance ratios and  is stan-





Using non-linear least squares regression method, 
and  can be obtained from the data series of nor-
malized number of proteins identified and the exper-
imentally determined ratios of the protein abun-
dances. The protein abundance ratio above which a
statistically significant increase in abundance should
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while the protein abundance ratio below which a
statistically significant decrease in abundance should
be considered 1/(2  ). Using these criteria, the
threshold above which a measured protein abun-
dance ratio reflects a statistically significant increase
in abundance should be considered to be 1.708 and
the threshold below which a measured abundance
ratio reflects a statistically significant decrease in
abundance should be considered to 0.585, for these
data. The present data indicate that 211 proteins and
Figure 5. Selected mass spectra of differentiall
mass spectra of the 16O/18O molecular ion pairs w
fragmentation ion series showing 4 Da ([M
apolipoprotein A-1, and (b) -1-antitrypsin.246 proteins are significantly increased and de-creased in abundance in serum from mice bearing
Lewis lung carcinoma, respectively. Hence, of the
proteins identified by two or more unique fully
tryptic peptides, approximately 28%, are observed to
change in abundance in mice with Lewis lung carci-
noma.
Several of the proteins that were found to be upregu-
lated in the serum obtained from the lung carcinoma
mouse model have been implicated in cancer progres-
sion. Vascular endothelial growth factor receptor 1
(VEGFR-1) was identified to be upregulated over 7-fold
eled LMW serum 16O/18O peptides. Full range
[MH]1) or 2 Da their corresponding MS/MS
H]2) mass shifts in the y-type ions for (a)y lab
ith (
 2in the mouse lung carcinoma model. VEGF is a key
(con
1228 HOOD ET AL. J Am Soc Mass Spectrom 2005, 16, 1221–1230angiogenic factor that is expressed and secreted by
nearly all tumors at high levels and stimulates angio-
genesis [24]. Members of the VEGF family’s angiogenic
signals are mainly mediated by activation of the struc-
turally related homologous tyrosine kinase receptors,
VEGFR-1 and VEGFR-2. A previous study has shown
that blocking VEGFR-1 activity reduces lung metastasis
[25]. These results are consistent with the discovery of
increased amounts of VEGFR-1 in the serum of the
mouse lung cancer model compared to the matched
control found in this study. Several of the proteins
identified to be differentially abundant in the Lewis
lung cancer mouse model are currently being validated
with the hope of linking their dysregulation back to the
Figure 5tumor site.Conclusions
The heart of proteomics represents a discovery science
that enables investigators to gather information on
hundreds, if not thousands, of proteins in a relatively
high-throughput, nonbiased, manner. This basic char-
acteristic has brought great hope that proteomics in-
cludes the sets of technologies that will enable the
discovery of biomarkers for the diagnosis of early
stages of diseases, such as cancer, a reality. Obviously,
developments in MS instrumentation have been critical
for enabling the broad identification of proteins in
complex mixtures such as serum. What is sometimes
under-appreciated, however, is the sample processing
tinued)steps conducted prior to any portion of the sample
1229J Am Soc Mass Spectrom 2005, 16, 1221–1230 QUANTITATIVE ANALYSIS OF THE LMW MOUSE PROTEOMEbeing introduced into the mass spectrometer. In this
study, we utilized ultrafiltration to enrich for the LMW
component of serum. This targeted fractionation is not
only simple, but removes a large proportion of the high
abundance proteins that are primarily responsible for
making the comprehensive characterization of serum
and plasma so challenging. Of equal importance is the
use of an off-line MudPIT approach to separate the
resultant peptides into manageable fractions for the
spectrometer to identify individual peptides. Although
many other groups have explored the use of alternative
techniques to provide broad proteome characterization,
the components of MudPIT (i.e., SCX and RPLC)
remain the optimal choice for fractionation of complex
peptide mixtures. If proteomics is to find effective
disease biomarkers without any prior knowledge as to
what their identity may be, methods such as LMW
fractionation and off-line MudPIT will be crucial to
gathering the critical mass of data necessary to make
assumptions about the relative abundances of proteins
in samples obtained from normal and disease-afflicted
individuals that can be validated over larger popula-
tions.
Although comparative proteomic analysis of human
serum promises the ability to discover new and more
effective biomarkers for the early indication of disease
and response to therapy, such investigations are com-
plicated because of the intrinsic variability in each
serum sample attributed to genetics, lifestyle, and en-
vironmental differences amongst people. A vital step in
making this distinction has relied on the use of animal
models such as the mouse where these biological vari-
ables can be carefully controlled to allow increased
rigor with which comparisons and pathophysiological
conclusions can be made. Mouse models, either trans-
genic or xenograft, represent an invaluable experimen-
Figure 6. Distribution of ratios of 18O/16O labeled proteins. Plot
of the normalized percent of the number of proteins identified by
two or more unique peptides versus their 18O/16O ratios. Abun-
dance ratios greater than 1.708 and less than 0.585 are considered
statistically significant and result in 211 proteins and 246 proteins
that are over- and underexpressed in the LMW mouse serum
proteome respectively.tal system for understanding human cancer pathogen-esis because, unlike human samples derived from
clinical trials, experimental artifacts related to genetic
background and environment can be more carefully
accounted for, thus minimizing the variability seen
within samples acquired from human patients. Along
these lines, we have developed a methodology to per-
mit direct quantitative measurement of abundance
changes in serum proteins from mouse models of
human cancer utilizing trypsin-mediated stable oxygen
isotope labeling. In this work, a global quantitative
proteomic investigation of the LMW serum proteomes
from control mice and those bearing human Lewis lung
carcinoma was conducted. This investigation resulted
in the identification of more than 6000 proteins; all from
peptides bearing full tryptic termini. In an effort to
increase the confidence in the population of proteins
utilized in the quantitative comparison, we culled from
this list only those proteins identified from two or more
tryptic peptides, which equates to 1647 proteins. From
this list of proteins identified with high confidence, 211
and 246 were quantitatively determined to be present at
an increased and decreased level of abundance, respec-
tively, in the serum of mice bearing Lewis lung carci-
noma. Current studies are focused on further analysis
of this differentially abundant dataset to determine if
any of these serum proteins can be directly linked to the
presence of the lung carcinoma.
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